75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail) 3
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail) 4
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail) 5
link:presentationLink
link:calculationLink
link:definitionLink
75090 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75100 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail) 6
link:presentationLink
link:calculationLink
link:definitionLink
75110 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Overview
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Liquidity
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value of Financial Instruments
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Warrants
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Inventory
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Long term Debt
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Net Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Fair Value of Financial Instruments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Warrants (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Inventory (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Long-term Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Net Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Liquidity - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Product Revenue Allowance and Reserve Categories (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Fair Value of Financial Instruments - Schedule of Marketable Securities Classified as Available-for-sale Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Warrants - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Warrants - Fair Value of Convertible Preferred Stock Warrant Liability (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Inventory - Schedule of Inventory (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Commitments and Contingencies - Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Long-term Debt - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Long-term Debt - Schedule of outstanding long-term debt (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Long-term Debt - Schedule Of Interest Expense Related to the Long-term Debt (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Stockholders' Equity - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Stockholders' Equity - Summary of Outstanding Common Stock Warrants (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Stockholders' Equity - Summary of Stock Option and Restricted Stock Unit Transactions (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Net Loss per Share - Schedule of Weighted-Average Common Shares Outstanding (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Segment Reporting - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Segment Reporting - Schedule of Cash Operating Expenses Reconciled to Net Loss on Consolidated Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Subsequent Events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Statement [Line Items]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Term
Liabilities, Fair Value Disclosure [Abstract]
Liabilities
Debt Instrument [Axis]
Debt Instrument
Increase (Decrease) in Accounts Receivable
Accounts receivable
Plan Name [Domain]
Plan Name
Debt instrument additional borrowing amount
Debt Instrument, Additional Borrowing Amount
Debt instrument, additional borrowing amount.
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Tax withholding payments for net share-settled equity awards
Tax withholding payments for net share-settled equity awards
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Summary of Outstanding Common Stock Warrants
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Summary of Product Revenue Allowance and Reserve Categories
Summary of Product Revenue Allowance and Reserve Categories [Table Text Block]
Summary of product revenue allowance and reserve categories.
Issuance of restricted stock units under equity incentive plans (shares)
Issuance of restricted stock units shares under equity incentive plan.
Issuance Of Restricted Stock Units Shares Under Equity Incentive Plan
Issuance of restricted stock units under equity incentive plan
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Revenues [Abstract]
Revenue
Cash paid for interest
Interest Paid, Excluding Capitalized Interest, Operating Activities
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Unrecognized stock based compensation expense
Number of Operating Segments
Number of operating segments
Tranche A [Member]
Share-Based Payment Arrangement, Tranche One [Member]
May 2023 Tranche A Pre-funded Warrants [Member]
Stockholders' Equity, Reverse Stock Split
Reverse stock split
Shares, Outstanding
Balances at end (shares)
Balances at beginning (shares)
Other non-cash reconciling items
Other Noncash Income (Expense)
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Operating lease right-of-use asset increase.
Operating Lease Right-Of-Use Asset Increase
Increase in right of use assets
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Lessee, Operating Lease, Description
Operating lease, description
Area of Real Estate Property
Area of operating lease
Stock based compensation capitalized into inventory
Share-Based Payment Arrangement, Amount Capitalized
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2025 (remainder of the year)
Warrants aggregate exercise price
Warrants aggregate exercise price.
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Stock, Class of Stock [Table]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Summary of Changes in Fair Value of Level 3 Financial Instruments
Product and Service [Axis]
Commitments and contingencies.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Noncash Investing and Financing Items [Abstract]
Supplemental disclosure of non-cash operating and financing information
Employee Stock [Member]
Employee Stock Purchase Plan [Member]
Interest expense
Interest Expense, Nonoperating
Interest Expense, Nonoperating, Total
Title and Position [Axis]
Class of Warrant or Right [Axis]
Class of Warrant or Right
Sale of Stock [Domain]
Sale of Stock
Debt Instrument Maturity Extension Period
Debt instrument maturity extension period.
Debt instrument maturity extension period
Long-Term Debt, Gross
Principal amount of term loans
Long-term debt
2018 PIPE warrant liability.
Two Thousand Eighteen P I P E Warrant Liability [Member]
2018 PIPE Warrant Liability [Member]
2018 PIPE Warrants [Member]
Interest paid
Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total
Inventory, Policy [Policy Text Block]
Inventory
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Entity Central Index Key
Entity Central Index Key
Proceeds from offering after deducting underwriting discount and other estimated offering expenses.
Proceeds From Offering After Deducting Underwriting Discount And Other Estimated Offering Expenses
Proceeds from offering after deducting underwriting discount and other estimated offering expenses
Increase decrease in accrued clinical trial site costs.
Increase Decrease In Accrued Clinical Trial Site Costs
Accrued clinical trial site costs
Debt Instrument, Maturity Date Range, End
Debt instrument maturity end date
Increase (Decrease) in Operating Capital [Abstract]
Change in operating assets and liabilities:
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Common Stock, Shares, Issued
Common stock, shares issued
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]
Measurement Input, Expected Dividend Rate [Member]
Expected Dividend Yield [Member]
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses, other current assets and other assets
Aggregrate Offering Price
Aggregrate Offering Price
Aggregrate offering price.
Business Description and Basis of Presentation [Text Block]
Overview
Income Statement [Abstract]
Percentage of aggregate gross proceeds to pay commission
Percentage of Aggregate Gross Proceeds to Pay Commission
Percentage of aggregate gross proceeds to pay commission.
Entity Address, State or Province
Entity Address, State or Province
Class of Warrant or Right [Table]
Class Of Warrant Or Right [Table]
Marketable Securities
Marketable Securities, Total
Marketable securities
Debt instrument additional borrowing available amount
Debt Instrument Additional Borrowing Available Amount
Debt instrument additional borrowing available amount.
Liability Class [Axis]
Liability Class
Debt instrument date of first borrowings
Debt Instrument Date of First Borrowings
Debt Instrument Date of First Borrowings
Inventory, Raw Materials, Gross
Raw materials
Payments of Debt Issuance Costs
Payment of debt issuance costs
Amortization of Debt Issuance Costs
Amortization of debt issuance costs
Cover [Abstract]
Subsequent Event [Line Items]
Earnings Per Share, Basic
Net loss per common share basic
Earnings Per Share, Basic, Total
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Operating Expenses [Abstract]
Operating expenses
Increase in operating lease liability.
Increase In Operating Lease Liability
Increase in lease liability
Share based compensation arrangement by share based payment award options non vested aggregate intrinsic value.
Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value
Milestone Achieved on or After December 17, 2025 [Member]
Milestone Achieved on or After December Seventeen Two thousand Twenty Five [Member]
Milestone Achieved on or After December Seventeen Two thousand Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Sharebased Compensation Arrangementby Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Roll Forward
Weighted-Average Exercise Price per Share
Share-Based Payment Arrangement, Expense
Stock-based compensation expense
Loan Available In Additional Tranches
Loan Available In Additional Tranches
Loan available in additional tranches
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (shares)
Stock Issued During Period, Shares, Stock Options Exercise and Restriced Stock Awards Vesting
Stock issued during period, shares, stock options exercise and restriced stock awards vesting.
Total long-term debt, net
Long-Term Debt
Amount borrowed
Two Thousand Twenty Two Pre Funded Warrants.
Two Thousand Twenty Two Pre Funded Warrants [Member]
2022 Pre-funded Warrants [Member]
Liquidity
Going concern and management’s plans.
Going Concern And Managements Plans [Text Block]
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Plan Name [Axis]
Plan Name
Segment Reporting [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Ending balance
Beginning balance
Assets, Current [Abstract]
Current assets
Asset purchase.
Asset Purchase [Axis]
Asset Purchase
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Net cash used in operating activities
Restricted stock units canceled/forfeited (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Options exercisable at end of period (shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Product and Service [Domain]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive income
Lessee, Operating Lease, Term of Contract
Operating lease, term of contract
Debt Instrument [Line Items]
Debt Instrument, Term
Debt instrument term
Property, Plant and Equipment, Net
Property and equipment, net
Property, Plant and Equipment, Net, Total
Lessee, Operating Lease, Liability, to be Paid, Year Four
2029
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Fair Value, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
May 2023 Tranche B Warrants [Member]
May 2023 Tranche B warrants
May Two Thousand Twenty Three Tranche B Warrants [Member]
May two thousand twenty three tranche b warrants.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis
Vesting
Vesting [Axis]
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Stock Options [Member]
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized loss on marketable securities
Measurement Input Type [Domain]
Measurement Input Type
Accounts Receivable [Policy Text Block]
Accounts Receivable, net
Statement of Cash Flows [Abstract]
Counterparty Name [Axis]
Counterparty Name
Convertible Debt Securities [Member]
Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Share Based Compensation Arrangement By Share Based Payment Recognized As Stock Based Compensation Expense
Share based compensation arrangement by share based payment recognized as stock based compensation expense.
Granted fair value shares recognized as stock-based compensation expense
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of common stock purchased upon issuance of warrants
Selling, General and Administrative Expenses [Member]
Selling, General and Administrative Expenses [Member]
Equity Components [Axis]
Equity Components
Entity Address, Address Line One
Entity Address, Address Line One
Employee-related Liabilities, Current
Accrued compensation
Employee-related Liabilities, Current, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Restricted stock units granted
Stock units granted
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Provisions
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value
Share based compensation arrangement by share based payment award options exercisable aggregate intrinsic value.
Options exercisable at end of period
Subsequent Event Type
Subsequent Event Type [Axis]
Equity Option [Member]
Options to Purchase Common Stock [Member]
Nonoperating Income (Expense)
Total other income (expense), net
Less total other income, net
Less total other income, net
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Ending balance
Beginning balance
Amendment Flag
Amendment Flag
Warrant issuance description
Class Of Warrant Or Right Exercise Price Description
Class of Warrant or Right, Exercise Price Description
Operating Lease, Liability, Noncurrent
Long-term operating lease liabilities
Long-term lease liabilities
Text Block [Abstract]
Debt Instrument, Name [Domain]
Debt Instrument, Name
Additional Paid in Capital, Common Stock
Additional paid-in-capital
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]
Percentage Of Probability Of Achieving Remaining Milestone
Percentage of probability of achieving remaining milestone.
Percentage of probability of achieving remaining milestone
Net loss
Net loss
Exercise of stock options (shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Options exercised
Exercise of stock options (shares)
Options exercised
Per share exercise price for Pre-funded warrant.
Per Share Exercise Price For Pre Funded Warrant
Per share exercise price for pre-funded warrant
Per share exercise price for pre-funded warrant
Research and Development Expense [Member]
Research and Development [Member]
Two thousand twenty three tranche B warrants.
Two Thousand Twenty Three Tranche B Warrants Member
2023 Tranche B warrants [Member]
2023 Tranche B Warrants [Member]
Debt instrument maturity start date
Debt Instrument, Maturity Date Range, Start
Equity Component [Domain]
Equity Component
Statistical Measurement [Domain]
Statistical Measurement
Interest Expense, Debt
Total interest expense
Interest expense
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Contractual term of option
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Rule 10b51 Arr Modified Flag
Rule 10b51 Arr Modified Flag.
Preferred stock, shares issued
Preferred Stock, Shares Issued
Cash paid for amounts included in the measurement of lease liabilities:
Cash paid for amounts included in measurement of lease liabilities.
Cash paid for amounts included in the measurement of lease liabilities:
Operating Lease, Payments
Operating cash flows from operating leases
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Two thousand twenty inducement equity incentive plan.
Two Thousand Twenty Inducement Equity Incentive Plan [Member]
2020 Inducement Equity Incentive Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Number of shares purchases by employees
Ownership Interest Percentageof Voting Rightsof Stock
Ownership interest, percentage of voting rights of stock.
Ownership interest of voting rights of all classes of stock (percent)
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Options exercisable at end of period (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Options canceled/forfeited (in dollars per share)
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Total comprehensive loss
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Number of shares available for issuance under the plan on the first day of each year
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Antidilutive Securities [Axis]
Antidilutive Securities
Schedule of Weighted-Average Common Shares Outstanding
Schedule of weighted-average common shares outstanding [Table Text Block]
Proceeds from issuance or sale of equity
Proceeds from Issuance or Sale of Equity
Proceeds from Issuance or Sale of Equity, Total
Gross proceeds from common stock public offering
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Summary of Restricted Stock Unit Transactions
Entity Interactive Data Current
Entity Interactive Data Current
Product [Member]
Product [Member]
Lease Expiration Date
Operating lease, expiration date
Lessee, operating lease, extension expiration, month and year.
Lessee, Operating Lease, Extension Expiration, Month and Year
Operating lease, extension expiration
Accounting Standards Update [Domain]
Document Quarterly Report
Document Quarterly Report
Restricted Stock units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Restricted stock units vested (in dollars per share)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash and cash equivalents, end of period
Cash and cash equivalents, beginning of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total
Statistical Measurement [Axis]
Statistical Measurement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Operating Lease, Cost
Operating lease cost
Debt Instrument, Payment Terms
Debt instrument payment terms
Assets, Fair Value Disclosure
Total assets
Total assets
Lease, Cost
Total operating lease cost
Derivative Financial Instruments, Liabilities [Member]
Derivative Financial Instruments, Liabilities [Member]
Reconciliation of Undiscounted Future Minimum Lease Payments Remaining under Operating Lease
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Board of Directors [Member]
Director [Member]
Underwriter discount and other offering expenses
Underwritter Discount and Other Offering Expenses
Underwritter discount and other offering expenses.
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Number of shares available for grant
Basis of Presentation and Significant Accounting Policies [Text Block]
Basis of Presentation and Summary of Significant Accounting Policies
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Restricted stock units granted (in dollars per share)
Weighted average grant-date fair value of all restricted stock units granted
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Future stock-based compensation, requisite service period
Stock issued issuance costs.
Stock Issued Issuance Costs
Offering costs
Statement of Income Location, Balance [Axis]
Income Statement Location
Assets
Total assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected life (years)
Schedule of Long-Term Debt Instruments [Table]
Restricted stock units vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Restricted stock units vested
2014 equity incentive plan.
Two Thousand And Fourteen Equity Incentive Plan [Member]
2014 Equity Incentive Plan [Member]
Common stock warrant liability [Member]
Common Stock Warrant Liability [Member]
Common Stock Warrant Liability [Member]
Recently Adopted Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Entity Address, City or Town
Entity Address, City or Town
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Equity [Abstract]
Debt instrument interest period
Debt Instrument Interest Period
Debt instrument interest period.
Assets, Fair Value Disclosure [Abstract]
Assets
Proceeds from sale of common stock and pre-funded warrants.
Proceeds From Sale Of Common Stock And Pre Funded Warrants
Proceeds from sale of common stock and pre-funded warrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Restricted stock units canceled/forfeited
Essentialis, Inc.
Essentialis Inc [Member]
Essentialis, Inc. [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount
Balance as of June 30, 2025
Balance as of December 31, 2024
Shareholders' Equity and Share-Based Payments [Text Block]
Stockholders' Equity
Debt instrument, face amount
Debt Instrument, Face Amount
Options exercisable at end of period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term
Weighted average remaining vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Fair value of restricted stock units vested
Operating Lease, Weighted Average Discount Rate, Percent
Operating lease, weighted average discount rate
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Fair Value Disclosures [Abstract]
Stock Issued During Period, Value, New Issues
Sale of common stock, net of issuance costs
Jefferies LLC [Member]
Jefferies LLC.
Jefferies LLC [Member]
Stock Issued During Period, Value, Stock Options Exercised
Exercise of stock options
Exercise of stock options
Liabilities, Current [Abstract]
Current liabilities
Kristen yen.
Kristen Yen [Member]
Kristen Yen [Member]
Document Type
Document Type
Accounting Standards Update [Axis]
Title of 12(b) Security
Title of 12(b) Security
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Lease, Cost [Table Text Block]
Schedule of Components of Lease Expense
Statement of Stockholders' Equity [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Balance at end of period
Balance at the beginning of period
Document Fiscal Period Focus
Document Fiscal Period Focus
Intrinsic value of stock options exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Research and Development Expense
Research and development
Research and Development Expense, Total
Tax withholding payments for net share-settled equity awards
Payment, Tax Withholding, Share-Based Payment Arrangement
Total long-term debt, net
Long-Term Debt, Excluding Current Maturities
Long-term debt, net
Total long-term debt, net
Share-Based Payment Arrangement, Expense, Tax Benefit
Income tax benefits recognized from stock-based compensation
CALIFORNIA
Redwood City, California [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of options granted
Options granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum
Percentage of outstanding stock maximum
Asset Class [Domain]
FDA Approval OF VYKATXR Tranche one [Member]
Fda approval of vykatxr tranche one.
FDA Approval OF VYKATXR Tranche one [Member]
Subsequent Event Type [Domain]
Subsequent Event Type
Measurement Input, Expected Term [Member]
Contractual Term [Member]
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model
Patricia c. hirano.
Patricia C. Hirano [Member]
Patricia C. Hirano [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]
Debt Instrument, Fee Percentage
Debt instrument, fee percentage.
Debt instrument fee
Rent payments
Payments for Rent
Weighted Average Exercise Price per Share
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants exercised
Weighted Average Exercise Price, Balance at the beginning of period
Weighted Average Exercise Price, Balance at the end of period
Consultant [Member]
Consultant.
Assets, Noncurrent [Abstract]
Long-term assets
Class of Warrant or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Sale of Stock [Axis]
Sale of Stock
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Marketable securities current
Marketable securities
Marketable Securities, Current
Final Principal Fee Payment Percentage
Final principal fee payment percentage.
Final principal fee payment percentage
Warrants and rights immediately exercisable term
Warrants And Rights Immediately Exercisable Term
Warrants and rights immediately exercisable term.
Two Thousand Twenty Two Common Warrants.
Two Thousand Twenty Two Common Warrants [Member]
2022 Common Warrants [Member]
Warrants and Rights Note Disclosure [Abstract]
Selling, General and Administrative Expense
Selling, General and Administrative Expense, Total
Selling, general and administrative
Underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering [Member]
Two thousand twenty three tranche A warrants.
Two Thousand Twenty Three Tranche A Warrants [Member]
2023 Tranche A Warrants [Member]
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction, Total
Depreciation and amortization
Debt instrument frequency of periodic payment
Debt Instrument, Frequency of Periodic Payment
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Entity Address, Address Line Two
Entity Address, Address Line Two
Class of warrant or right warrants expiration month and year.
Class Of Warrant Or Right Warrants Expiration Month And Year
Expiration period
Expiration Date
Liabilities and Equity [Abstract]
Liabilities and stockholders’ equity
Document Period End Date
Document Period End Date
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Long-term liabilities
Liabilities, Noncurrent [Abstract]
Sales Agreement [Member]
Sales Agreement [Member]
Sales agreement.
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding
Asset purchase.
Asset Purchase [Domain]
Asset Purchase
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Long-term debt outstanding
Long Term Debt Outstanding
Long term debt outstanding.
Thereafter
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
May 2023 Tranche A Warrants [Member]
May 2023 Tranche A warrants
May Two Thousand Twenty Three Tranche A Warrants [Member]
May two thousand twenty three tranche a warrants.
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]
Trading Symbol
Trading Symbol
Equity, Attributable to Parent
Balances at ending
Balances at beginning
Total stockholders’ equity
Class of warrant or right exercised.
Class Of Warrant Or Right Exercised
Warrants exercised
Exercise of common stock warrants (shares)
Cash operating expenses
Segment Reporting Cash Operating Expenses
Segment reporting cash operating expenses.
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Common Shares
Number of Common Warrant Shares
Balance at the beginning of period, in shares
Balance at the end of period, in shares
Warrants outstanding
Other long-term liabilities
Other Liabilities, Noncurrent
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units [Member]
Outstanding Restricted Stock Units [Member]
Variable Lease, Cost
Variable lease cost
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Lessee, operating lease month and year of expiration.
Lessee Operating Lease Month And Year Of Expiration
Operating lease, expiration
Five Percentage Interest On Total Loan Amount on Final Principal Payment [Member]
Five percentage interest on total loan amount on final principal payment.
5% Interest on Total Loan Amount on Final Principal Payment [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Summary of Stock Based Compensation Expense
Capital Units, Authorized
Capital stock, shares authorized
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Change in value of liabilities
Measurement Input Type [Axis]
Measurement Input Type
Geographical [Axis]
Geographical
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Unrealized Losses
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Future stock-based compensation for unvested employee options granted and outstanding
Number Of Tranches
Number Of Tranches
Number of tranches
Purchase Price Contingent Liability [Member]
Purchase price contingent liability [Member]
Purchase price contingent liability.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Securities Purchase Agreement [Member]
Securities Purchase Agreement [Member]
Securities Purchase Agreement [Member]
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Class of Stock [Line Items]
Measurement Input, Price Volatility [Member]
Volatility [Member]
Other Commitment, Total
Other Commitment
Non-cancelable other commitments
Scenario [Axis]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Dividend rate
Expected dividend yield
Marketable Securities, Policy [Policy Text Block]
Marketable Securities
Security Exchange Name
Security Exchange Name
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Schedule of Marketable Securities Classified as Available-for-sale Securities
Counterparty Name [Domain]
Counterparty Name
Fair Value by Liability Class [Domain]
Fair Value by Liability Class
Total operating expenses
Operating Expenses
Total operating expenses
Measurement Input, Risk Free Interest Rate [Member]
Risk-free Rate [Member]
Schedule Of Significant Accounting Policies [Table]
Schedule Of Significant Accounting Policies [Table]
Schedule Of Significant Accounting Policies [Table]
Noncash Lease Expense
Non-cash lease expense
Noncash lease expense
Non-cash lease expense.
Non-cash lease expense
Fair Value Disclosures [Text Block]
Fair Value of Financial Instruments
Lessee, Operating Lease, Liability, to be Paid, Year Three
2028
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant date fair value per option granted (in dollars per share)
Subsequent Event [Member]
Subsequent Event [Member]
Maximum [Member]
Maximum [Member]
Liabilities and Equity
Total liabilities and stockholders’ equity
Customary Payment Terms
Customary payment terms.
Customary payment terms
Debt Instrument Date of Final Borrowings
Debt Instrument Date of Final Borrowings
Debt instrument date of final borrowings
Right-of-use asset
Operating Lease, Right-of-Use Asset
Operating lease right-of-use assets
Lessee, operating lease commencement month and year.
Lessee Operating Lease Commencement Month And Year
Operating lease beginning date
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Net loss per common share diluted
Liabilities
Total liabilities
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Stock Issued During Period, Value, Stock Options Exercise and Restriced Stock Awards Vesting
Stock issued during period, value, stock options exercise and restriced stock awards vesting.
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Assets, Current
Total current assets
Net Cash Provided by (Used in) Investing Activities
Net cash provided by (used in) investing activities
Sale of common stock, net of issuance costs (shares)
Stock Issued During Period, Shares, New Issues
Issuance of common stock (shares)
Entity Filer Category
Entity Filer Category
Anish bhatnagar.
Anish Bhatnagar [Member]
Anish Bhatnagar [Member]
Food and Drug Administration (FDA) Approval of VYKAT XR [Member]
Food and drug administration (FDA) approval of VYKAT XR.
FDA approval of VYKAT XR [Member]
Payments to Acquire Marketable Securities
Purchases of marketable securities
Nonoperating Income (Expense) [Abstract]
Other income (expense), net
Current Fiscal Year End Date
Current Fiscal Year End Date
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Less interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less interest
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Stock-based compensation
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Balance at March 31, 2024
Options outstanding at beginning of period
Options outstanding at end of period
Interest Expense, Debt, Excluding Amortization
Interest expense based on contractual loan rate
Entity Registrant Name
Entity Registrant Name
Options vested at end of period
Share based compensation arrangement by share based payment award options vested aggregate intrinsic value.
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
Common Stock Warrants [Member]
Common stock warrants.
Common Stock Warrants [Member]
Oxford [Member]
Oxford Financing LLC And Its Affiliates [Member]
Oxford Financing LLC And Its Affiliates [Member]
Number of reportable segments
Number of Reportable Segments
Cost of Revenue
Cost of goods sold
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Net Loss per Share
Earnings Per Share [Text Block]
Entity Emerging Growth Company
Entity Emerging Growth Company
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued Clinical Trial Costs Current
Accrued clinical trial site costs
Shares issued from sale of common stock.
Shares Issued From Sale Of Common Stock
Shares issued from sale of common stock
ASU No. 2016-13 [Member]
Accounting Standards Update 2016-13 [Member]
Money Market Funds [Member]
Money Market Funds [Member]
Other Liabilities, Current
Other current liabilities
Weighted-average common shares outstanding used to calculate basic shares
Weighted Average Number of Shares Outstanding, Basic
Weighted-average common shares outstanding used to calculate basic net loss per common share
Weighted Average Number of Shares Outstanding, Basic, Total
Vesting
Vesting [Domain]
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating lease liabilities
Common Stock, Shares Authorized
Common stock, shares authorized
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Tax withholding payments for net share-settled equity awards (shares)
Accrued interest payable
Interest Payable, Current
Schedule Of Outstanding Long-term Debt
Schedule of Long-Term Debt Instruments [Table Text Block]
Proceeds from the sale of common stock, net of issuance costs
Proceeds from Issuance of Common Stock
Proceeds from sale of common stock, net of costs
Maturities of marketable securities
Proceeds from Sale and Maturity of Marketable Securities
Cash and Cash Equivalents [Abstract]
Credits/payments
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Debt Disclosure [Abstract]
Long-Term Debt [Text Block]
Long-term Debt
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Options vested and expected to vest at end of period (in dollars per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Options granted (in dollars per share)
Public Offering
Public Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Options outstanding at end of period
Proceeds received prior to and for the issuance of common stock and pre-funded warrants
Proceeds received prior to for issuance of common stock and pre-funded warrants
Proceeds received prior to for issuance of common stock and pre-funded warrants
General and Administrative Expense [Member]
General and Administrative [Member]
Share-Based Payment Arrangement [Abstract]
Sale and issuance of warrants
Proceeds from Issuance of Warrants
Debt Securities, Available-for-Sale
Estimated Fair Value
Estimated Fair Value
Accounting Policies [Abstract]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Stock Option and Restricted Stock Unit Transactions
Rent payments annual increase percentage
Operating Lease Annually Increase Percentage
Operating lease annually increase percentage.
Cash and Cash Equivalents [Line Items]
Cash And Cash Equivalents [Line Items]
Schedule of Interest Expense Related to the Long-term Debt
Schedule Of Long Term Debt Interest Expenses [Table Text Block]
Schedule of long term debt interest expenses.
Long-term marketable securities
Marketable Securities, Noncurrent
Equity, Attributable to Parent [Abstract]
Stockholders’ equity
Percentage of increase in applicable rate of interest under termination of the lenders' commitments
Percentage of Increase in Applicable Rate of Interest under Termination of the Lenders' Commitments
Percentage of increase in applicable rate of interest under termination of the lenders' commitments.
Statement [Table]
Statement [Table]
Asset acquisition contingent consideration arrangements earn out payment,
Asset Acquisition Contingent Consideration Arrangements Earn Out Payment
Maximum potential cash earnout payments
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Options vested and expected to vest at end of period
Shares issued from sale of pre-funded warrants.
Shares Issued From Sale Of Pre-Funded Warrants
Shares issued from sale of pre-funded warrants
Subsequent Event [Table]
Stock issued during period, value, exercise of common stock warrants and pre-funded common stock warrants.
Stock Issued During Period, Value, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants
Exercise of common stock warrants and pre-funded common stock warrants
Convertible preferred stock, shares authorized
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Revenue from Contract with Customer, Including Assessed Tax
Total revenue
Total revenue
Product revenue, net
Securities Act File Number
Entity File Number
Segment Reporting Disclosure [Text Block]
Segment Reporting
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Earnings Per Share [Abstract]
Warrants and Rights Outstanding, Term
Measurement term
Exercise Of Common Stock Warrants
Exercise of common stock warrants.
Exercise of common stock warrants
Inventory Disclosure [Abstract]
Statement of Financial Position [Abstract]
Contingent upon Certain Commercial Milestones [Member]
Contingent upon certain commercial milestones.
Contingent upon certain commercial milestones [Member]
Operating Income (Loss)
Operating loss
Operating loss
Price per share
Shares Issued, Price Per Share
Price per unit
Performance-based restricted stock units.
Performance-Based Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Volatility
Entity Shell Company
Entity Shell Company
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Fair Value of Convertible Preferred Stock Warrant Liability
Entity Tax Identification Number
Entity Tax Identification Number
Assets [Abstract]
Assets
Schedule Of Supplemental Cash Flow Information Related To Leases
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of supplemental cash flow information related to leases.
Class of Warrant or Right [Domain]
Class of Warrant or Right
Public offering price per pre-funded warrant.
Public Offering Price Per Pre Funded Warrant
Public offering price per pre-funded warrant
Entity Current Reporting Status
Entity Current Reporting Status
Corporate Debt Securities And Commercial Paper [Member]
Corporate Debt Securities And Commercial Paper [Member]
Corporate debt securities and commercial paper [Member]
Corporate Debt Securities and Commercial Paper [Member]
Oct 2023 Pre-funded Warrants [Member]
October 2023 Pre-funded Warrants [Member]
October Two Thousand Twenty Three Pre-funded Warrants [Member]
Oct 2023 Pre-funded warrants.
Asset Acquisition, Contingent Consideration, Liability, Noncurrent
Contingent liability for Essentialis purchase price
Essentialis purchase price contingency liability
Subsequent Events [Abstract]
Inventory Disclosure [Text Block]
Inventory
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
Geographical [Domain]
Geographical
Document Fiscal Year Focus
Document Fiscal Year Focus
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Share-Based Payment Arrangement, Tranche Two [Member]
Tranche B [Member]
May 2023 Tranche B Pre-funded Warrants [Member]
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Preferred Stock, Value, Issued
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Options canceled/forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total
Cost of Goods Sold
Cost of Goods and Service [Policy Text Block]
Copay Assistance and Returns [Member]
Copay assistance and returns.
City Area Code
City Area Code
Warrants and Rights Outstanding, Measurement Input
Measurement input
Liabilities, Current
Total current liabilities
Milestones payment.
Milestones Payment
Milestones payment
Inventory, Net
Total
Inventory
Inventory, Finished Goods, Gross
Finished goods
Increase decrease in operating lease liabilities.
Increase Decrease In Operating Lease Liabilities
Operating lease liabilities
Debt instrument final interest payment
Debt Instrument, Periodic Payment, Interest
Debt instrument date of final required payment
Debt Instrument Date Of Final Required Payment1
Debt instrument date of final required payment1.
Local Phone Number
Local Phone Number
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock issued during period, shares, exercise of common stock warrants and pre-funded common stock warrants.
Stock Issued During Period, Shares, Exercise Of Common Stock Warrants And Pre-funded Common Stock Warrants
Exercise of common stock warrants and pre-funded common stock warrants (shares)
Proceeds from Warrant Exercises
Proceeds from exercise of common stock warrants
Proceeds from exercise of common stock warrants
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants
Sale and issuance of warrants to purchase common stock
Commitments and Contingencies Disclosure [Abstract]
Loan And Security Agreement [Member]
Loan And Security Agreement [Member]
Loan And Security Agreement [Member]
Loan issuance costs
Debt Issuance Costs, Net
Debt Issuance Costs, Net, Total
Debt Securities, Available-for-Sale, Amortized Cost
Amortized Cost
Amortized Cost
Operating Lease, Liability, Current
Operating lease, short-term liability
Operating lease liabilities
Exercisable warrants maximum aggregate exercise price
ExercisableWarrants Maximum Aggregate Exercise price
Exercisable warrants maximum aggregate exercise price.
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Foreign currency translation adjustment
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Debt Instrument interest rate stated percentage
Debt Instrument, Interest Rate, Stated Percentage
Retained Earnings [Member]
Accumulated Deficit [Member]
Schedule Of Significant Accounting Policies [Line Items]
Schedule Of Significant Accounting Policies [Line Items]
Schedule Of Significant Accounting Policies [Line Items]
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Document Transition Report
Document Transition Report
Debt Instrument, Date of First Required Payment
Debt instrument date of first required payment
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Percentage of fair market value
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Options exercised (in dollars per share)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Unamortized debt issuance costs
Minimum [Member]
Minimum [Member]
Commitments and contingencies.
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Common Stock [Member]
Common Stock [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Options vested and expected to vest at end of period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Ending balance (in dollars per share)
Beginning balance (in dollars per share)
Additional Paid-in Capital [Member]
Additional Paid-In Capital [Member]
Percentage of the probability of achieving the milestone.
Percentage Of Probability Of Achieving Milestone
Percentage of probability of achieving milestone
Rebates [Member]
Rebates.
Rebates
Two thousand twenty three tranche a pre funded warrants.
2023 Tranche A Pre-funded Warrants [Member]
Two Thousand Twenty Three Tranche A Pre-funded Warrants [Member]
Debt Securities, Available-for-Sale, Current
Total marketable securities
Underwriter [Member]
Underwriter [Member]
Underwriter [Member]
Warrants Issued to Underwriter to Purchase Common Stock [Member]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Discounts and Chargebacks [Member]
Discounts and chargebacks.
Other comprehensive loss
Other comprehensive income (loss)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Statement of Income Location, Balance [Domain]
Income Statement Location
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Other Assets, Noncurrent
Other long-term assets
Number of Installments
Number of Installments
Number of installments
Increase (Decrease) in Other Operating Liabilities
Other liabilities
Increase (Decrease) in Other Operating Liabilities, Total
Non Rule 10b51 Arr Modified Flag
Non Rule 10b51 Arr Modified Flag.
Schedule of Inventory, Current [Table Text Block]
Schedule of Inventory
FDA Approval OF VYKATXR Tranche Two [Member]
Fda approval of vykatxr tranche two.
FDA Approval OF VYKATXR Tranche Two [Member]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Two thousand and fourteen equity incentive plan and two thousand twenty inducement equity incentive plan.
Two Thousand And Fourteen Equity Incentive Plan And Two Thousand Twenty Inducement Equity Incentive Plan [Member]
2014 Plan and Inducement Plan [Member]
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Liquidity Disclosure [Text Block ]
Liquidity disclosure.
Liquidity
Scenario [Domain]
Title and Position [Domain]
Less transaction costs
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Warrants and Rights Outstanding
Fair value of estimated warrants
Proceeds from Exercise of Common Stock and Pre-Funded Stock Warrants
Proceeds from exercise of common stock and pre-funded stock warrants.
Proceeds from exercise of common stock and pre-funded stock warrants
Common Stock, Value, Issued
Common stock, $0.001 par value, 100,000,000 shares authorized, 50,437,066 and 45,703,811 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively
Increase (Decrease) in Employee Related Liabilities
Accrued compensation
Increase (Decrease) in Employee Related Liabilities, Total
Investment Income, Interest
Interest income, net
Public Offering of Common Stock [Member]
March Thousand Twenty Two Public Offering Of Common Stock [Member]
March thousand twenty two public offering of common stock.
Reverse stock split.
Reverse Stock Split Policy [Policy Text Block]
Reverse Stock Split
Total cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Cash and Cash Equivalent [Table]
Schedule Of Cash And Cash Equivalents [Table]
Total
Operating Lease, Liability
Right-of-use liability
Total
Measurement Frequency [Axis]
Measurement Frequency
Commitments and Contingencies
Commitments and contingencies (Note 6)
Two thousand eighteen PIPE warrant liability to purchase common stock.
Two Thousand Eighteen P I P E Warrant Liability To Purchase Common Stock [Member]
2018 PIPE Warrant Liability [Member]
Weighted-average common shares outstanding used to calculate diluted shares
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average common shares outstanding used to calculate diluted net loss per common share
Weighted Average Number of Shares Outstanding, Diluted, Total
Schedule of Cash Operating Expenses Reconciled to Net Loss on Consolidated Basis
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts receivable, net
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Options vested and expected to vest at end of period (shares)
Lessee, Operating Lease, Liability, to be Paid
Total lease payments
Increase (Decrease) in Inventories
Increase (Decrease) in Inventories, Total
Inventory
Mutual Consent of Soleno and Oxford [Member]
Mutual consent of Soleno and Oxford.
Mutual Consent of Soleno and Oxford [Member]
Jim Mackaness.
Jim Mackaness [Member]
Jim Mackaness [Member]
Incentive Stock Options [Member]
Incentive Stock Options [Member]
ISOs [Member]
Long-term Accrued Interest Payable
Long-term accrued interest payable.
Long-term accrued interest payable
Entity Small Business
Entity Small Business
March 2022 Common Warrants [Member]
March 2022 common warrants
March Two Thousand Twenty Two Common Warrants [Member]
March two thousand twenty two common warrants.
Stockholders' Equity Note, Stock Split, Conversion Ratio
Reverse stock split ratio
US Treasury Securities [Member]
US Treasury Securities [Member]
Warrants
Warrant Liability Disclosure [Text Block]
Warrant Liability Disclosure [Text Block]
Accretion of premium/discount on marketable securities
Accretion (Amortization) of Discounts and Premiums, Investments
Debt instrument maturity date description
Debt Instrument, Maturity Date, Description
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Ending balance (in dollars per share)
Beginning balance (in dollars per share)
Asset Class [Axis]
Major Customers, Policy [Policy Text Block]
Concentration of Major Customers and Off-Balance Sheet Risk
May Two Thousand Twenty Three Tranche B Pre Funded Exchange Warrants Member
May two thousand twenty three tranche B pre funded exchange warrants.
May 2023 Tranche B Pre-funded Warrants [Member]
Intangible Assets, Net (Excluding Goodwill)
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill), Total
Amortization of debt issuance costs and accretion of final interest payment
Amortization Of Debt Issuance Costs And Accretion Of Final Interest Payment
Amortization of debt issuance costs and accretion of final interest payment.
Measurement Frequency [Domain]
Measurement Frequency
May 2023 Tranche A Pre-funded Warrants [Member]
May Two Thousand Twenty Three Tranche A Pre Funded Exchange Warrants Member
May two thousand twenty three tranche A pre-funded exchange warrants.
Payment of deferred financing costs
Payment Of Deferred Financing Costs
Payment of deferred financing costs.
Work in process
Inventory, Work in Process, Gross
Fair Value, Inputs, Level 3 [Member]
Level 3 [Member]
Operating Lease, Weighted Average Remaining Lease Term
Operating lease remaining term
Asset acquisition contingent consideration change in fair value.
Asset Acquisition Contingent Consideration Change In Fair Value
Change in fair value of contingent consideration
Change in fair value of contingent consideration
Subsequent Events [Text Block]
Subsequent Events
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Net unrealized loss on marketable securities
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Costs and Expenses
Total operating expenses
Liabilities, Fair Value Disclosure
Total liabilities
Short-Term Lease, Cost
Short-term lease cost